

Starting Clinical Trials: The 70- day benchmark
1st April 2015 – 30th September 2015

REC Reference	Trial	Date of valid document set receipt	Date of NHS Permission	Date of first recruit	Total Days taken	Benchmark Met	Reasons for not achieving the 70 day benchmark
14/SC/1014	The JANUS 1 Study Incyte INCB 18424362	19/09/2014	10/10/2014	10/03/2015	172	No	Sponsor Delay: Study open to recruitment from 08/01/15. Previously awaited sponsor approval on the test images before our site could be activated.
13/SC/0379	RESPIRE (CARD 3360)	22/09/2014	15/10/2014	19/03/2015	178	No	Sponsor Delay: Initial delays in setting up contract by sponsor. Elective pacing was temporarily suspended between December 2014 and March 2015. First patient recruited 19/03/2015. Study has now changed to closed in Follow Up by the sponsor. Recruitment was closed earlier than target date as national recruitment achieved.
14/EM/1005	CCRN 3204- Phase 3 Masitinib /Placebo + Docetaxel in Metastatic Prostate Cancer V1 AB12003	25/09/2014	15/10/2014	10/03/2015	166	No	Sponsor Delay: Study was not open to recruitment. IMP delay from sponsor.
11/WM/0287	DESKTOP III - A randomized multicentre study to compare the efficacy of additional tumour debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer	02/10/2014	23/10/2014	17/02/2015	138	No	Sponsor Delay: Letter received from the trial centre stating our site numbers and that we are open for recruitment from 11/11/2014. End of recruitment originally advised as 01/02/2015 by sponsor. Later advised study had been extended. No patients were eligible in the interim between 11/11/2014 and 01/02/2015. Once confirmed study extended eligible patient identified 17/02/2015.
14/YH0085	FLAIR: Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab	13/11/2014	20/11/2014	19/05/2015	187	No	Sponsor Delay: Pharmacy green light 22/12/2014, drug delivered by the sponsor on 15 December and the sponsor initiated the site on 22 December. Study now open to recruitment. Rare condition. No eligible patients prior to first recruit.
14/EM/1130	An investigation of biomarkers in ACL patients and healthy controls.	22/09/2014	24/10/2014	10/02/2015	141	No	Unforeseen resignation of Research Fellow employed for study by University.
13/WA/0205	AML-18	08/01/2015	12/01/2015	17/06/2015	160	No	Lincoln site open to recruit from 13/03/2015. Pilgrim site activation 20/03/2015. Pharmacy Green Light 05/02/2015. There weren't any eligible patients identified during initial screening. This is not a common cancer so no eligible patients identified until 17/06/2015.

12/WM/0187	ROCSS Reinforcement of closure of stoma site	26/01/2015	05/02/2015	06/03/2015	39	Yes	
13/SC/0111	FOCUS4: Molecular selection of therapy in colorectal cancer	06/02/2015	25/02/2015			No	Sponsor Delay:R&D permission 25/02/2015. Site Activation approval given 14/05/2015 - sponsor delay. No eligible patients to date from screenings.
12/NE/0401	Folic Acid Clinical Trial (FACT)	23/02/2015	09/03/2015	01/06/2015	98	No	Sponsor Delay:Site Activation approval given 29/04/15. 1st recruit 01/06/15. 33 days to FPI from site activation.
14/LO/2011	CCRN 2833 DUAL antithrombotic therapy with dabigatran etexilate (RE-DUAL PCI)	13/03/2015	18/03/2015	27/04/2015	45	Yes	Site Activation approval given 28/04/2015
14/SC/1219	Airways Management in Cardiac Arrest patients -Airways-2	16/04/2015	08/05/2015	13/07/2015	88	No	Difficult to recruit patients due to low survival rate. EMAS perform randomisation.
14/NE/0097	Computer Game for Rehab Young People	11/06/2015	25/06/2015	11/08/2015	61	Yes	
14/WM/1055	NCRN 3246 Masitinib/Placebo + FOLFIRI in Metastatic Colorectal Cancer V1.1 AB12006	20/04/2015	27/04/2015			No	Pharmacy green light given from 23/07/2015. Delays from sponsor in responding to Pharmacy queries.
12/LO/1078	MUK five	25/06/2015	26/06/2015	21/07/2015	26	Yes	
13/YH/0229	GO2	24/03/2015	13/04/2015	09/09/2015	169	No	Request from Sponsor to add additional arms after approval resulting in delay.
14/WS/0111	Amber	08/07/2015	16/07/2015			No	Delay in sponsor approval. Given 11/08/2015. To date no eligible patients identified as all reviewed have failed eligibility criteria.
15/EM/0055	RIGHT-2	24/07/2015	06/08/2015			Within 70 days	Delays from trial centre - site due to open w/c 12th October
13/EM/0459	Posnoc	05/08/2015	07/08/2015			Within 70 days	CTA signed 24/08/2015
15/YH/0245	Evaluation of Factors affecting Ostomy Products	25/08/2015	26/08/2015	01/09/2015	7	Yes	
15/SC/0303	Revlimid (lenalidomide) NIS Post Authorization Safety Study (PASS)	26/08/2015	16/09/2015	29/09/2015	34	Yes	
15/EM/0069	CANC - 3694 - Obinutuzumab + GDC-0199 (ABT-199) vs Obinutuzumab + chlorambucil in CLL (CLL14)	16/09/2015	24/09/2015			Within 70 days	
14/SC/0171	Add Aspirin	19/08/2015	19/08/2015			Within 70 days	